JPWO2020089474A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020089474A5 JPWO2020089474A5 JP2021523957A JP2021523957A JPWO2020089474A5 JP WO2020089474 A5 JPWO2020089474 A5 JP WO2020089474A5 JP 2021523957 A JP2021523957 A JP 2021523957A JP 2021523957 A JP2021523957 A JP 2021523957A JP WO2020089474 A5 JPWO2020089474 A5 JP WO2020089474A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody molecule
- seq
- nucleotide sequence
- checkpoint inhibitor
- plasmid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004965 antibodies Human genes 0.000 claims 67
- 108090001123 antibodies Proteins 0.000 claims 67
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 29
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 21
- 229940121650 immune-checkpoint protein inhibitors Drugs 0.000 claims 21
- 241000700605 Viruses Species 0.000 claims 16
- 210000004027 cells Anatomy 0.000 claims 15
- 102100003105 TNFRSF1B Human genes 0.000 claims 11
- 101710038524 TNFRSF1B Proteins 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 9
- 210000001519 tissues Anatomy 0.000 claims 5
- 201000009910 diseases by infectious agent Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 102000004851 Immunoglobulin G Human genes 0.000 claims 3
- 230000003834 intracellular Effects 0.000 claims 3
- 230000001717 pathogenic Effects 0.000 claims 3
- 244000052769 pathogens Species 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 210000000066 Myeloid Cells Anatomy 0.000 claims 2
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000003042 antagnostic Effects 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 230000000903 blocking Effects 0.000 claims 2
- 102100007290 CD274 Human genes 0.000 claims 1
- 101710012053 CD274 Proteins 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 102000009490 IgG Receptors Human genes 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 1
- 230000003213 activating Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000038129 antigens Human genes 0.000 claims 1
- 108091007172 antigens Proteins 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18203993 | 2018-11-01 | ||
| EP18203993.3 | 2018-11-01 | ||
| PCT/EP2019/080004 WO2020089474A1 (en) | 2018-11-01 | 2019-11-01 | Novel antagonistic anti tnfr2 antibody molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022512905A JP2022512905A (ja) | 2022-02-07 |
| JPWO2020089474A5 true JPWO2020089474A5 (zh) | 2022-10-26 |
Family
ID=64109794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523957A Pending JP2022512905A (ja) | 2018-11-01 | 2019-11-01 | 新規アンタゴニスト抗ｔｎｆｒ２抗体分子 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220073634A1 (zh) |
| EP (1) | EP3873936A1 (zh) |
| JP (1) | JP2022512905A (zh) |
| KR (1) | KR20210087029A (zh) |
| CN (1) | CN112955469A (zh) |
| AU (1) | AU2019372184A1 (zh) |
| BR (1) | BR112021007995A2 (zh) |
| CA (1) | CA3117864A1 (zh) |
| IL (1) | IL282715A (zh) |
| MX (1) | MX2021005150A (zh) |
| WO (1) | WO2020089474A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023529010A (ja) | 2020-06-12 | 2023-07-06 | ナンチン リーズ バイオラブス カンパニー，リミティド | Ｔｎｆｒ２に結合する抗体およびその用途 |
| AU2022212842A1 (en) * | 2021-01-29 | 2023-08-31 | Shandong Simcere Biopharmaceutical Co., Ltd. | Humanized antibody against tnfr2 and use thereof |
| EP4067381A1 (en) | 2021-04-01 | 2022-10-05 | Julius-Maximilians-Universität Würzburg | Novel tnfr2 binding molecules |
| CN116333123A (zh) * | 2021-12-22 | 2023-06-27 | 宝船生物医药科技(上海)有限公司 | 抗tnfr2抗体及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101001872A (zh) * | 2004-04-16 | 2007-07-18 | 宏观基因有限公司 | FcγRIIB－特异性抗体及其使用方法 |
| CN1997667A (zh) * | 2004-05-10 | 2007-07-11 | 宏观基因有限公司 | 人源化FcγRⅡB特异性抗体及其使用方法 |
| DK2953634T3 (da) | 2013-02-07 | 2021-08-30 | Massachusetts Gen Hospital | Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler |
| CN114751989A (zh) * | 2015-03-31 | 2022-07-15 | 豪夫迈·罗氏有限公司 | 包含三聚体tnf家族配体的抗原结合分子 |
| WO2016187068A1 (en) * | 2015-05-15 | 2016-11-24 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
| EP3340999A4 (en) | 2015-08-28 | 2019-06-12 | The General Hospital Corporation | TYPE II ANTI-RECEPTOR AGONISTIC ANTIBODIES OF TUMOR NECROSIS FACTOR |
| WO2017083525A1 (en) | 2015-11-11 | 2017-05-18 | Opi Vi- Ip Holdco Llc | Composition and methods for anti-tnfr2 antibodies |
| KR102410778B1 (ko) | 2016-05-13 | 2022-06-21 | 더 제너럴 하스피탈 코포레이션 | 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체 |
| EP3475301B1 (en) * | 2016-06-22 | 2023-01-04 | Université Paris-Est Créteil Val de Marne | Prevention or treatment of hematologic malignancy relapse using a tnfr2 antagonist |
-
2019
- 2019-11-01 CA CA3117864A patent/CA3117864A1/en active Pending
- 2019-11-01 KR KR1020217012926A patent/KR20210087029A/ko active Search and Examination
- 2019-11-01 JP JP2021523957A patent/JP2022512905A/ja active Pending
- 2019-11-01 EP EP19805901.6A patent/EP3873936A1/en active Pending
- 2019-11-01 WO PCT/EP2019/080004 patent/WO2020089474A1/en unknown
- 2019-11-01 US US17/290,352 patent/US20220073634A1/en active Pending
- 2019-11-01 CN CN201980071097.6A patent/CN112955469A/zh active Pending
- 2019-11-01 BR BR112021007995-5A patent/BR112021007995A2/pt unknown
- 2019-11-01 MX MX2021005150A patent/MX2021005150A/es unknown
- 2019-11-01 AU AU2019372184A patent/AU2019372184A1/en active Pending
-
2021
- 2021-04-27 IL IL282715A patent/IL282715A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7366543B2 (ja) | Ｂｃｍａ結合分子及びその使用方法 | |
| EP3341020B1 (en) | Pd-l1 ("programmed death-ligand 1") antibodies | |
| JP7257364B2 (ja) | 抗ｃｄ１３７抗体 | |
| WO2018137576A1 (zh) | 抗pd-1单克隆抗体及其制备方法和应用 | |
| KR20190117493A (ko) | 항 pd-1 항체 및 그의 용도 | |
| JP2018531219A6 (ja) | Ｐｄ−ｌ１抗体 | |
| IL271347B2 (en) | Bispecific antibody checkpoints | |
| AU2016258115A1 (en) | Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof | |
| WO2011103701A1 (zh) | 全人源抗TNF-α单克隆抗体、其制备方法及用途 | |
| JPWO2019224718A5 (zh) | ||
| CN115991778A (zh) | 抗pd-l1抗体及其用途 | |
| US20220372161A1 (en) | Antibodies against the poliovirus receptor (pvr) and uses thereof | |
| KR20170138551A (ko) | Fab-dsFv 다량체 종에서 단량체 항체의 백분율을 증가시키는 방법 | |
| US20220403037A1 (en) | Anti-ccr8 antibodies and uses thereof | |
| CN113292649A (zh) | 新型冠状病毒的人源单克隆抗体及其应用 | |
| EP3856778A1 (en) | System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies | |
| JPWO2020089473A5 (zh) | ||
| JPWO2020089474A5 (zh) | ||
| CN113292650B (zh) | 新型冠状病毒的人源单克隆抗体及其应用 | |
| RU2021115554A (ru) | Новые молекулы антагонистических анти-tnfr2-антител | |
| RU2021115563A (ru) | Новые молекулы агонистических анти-tnfr2 антител | |
| WO2023071953A1 (zh) | 抗cd26抗体及其应用 | |
| CA3206413A1 (en) | Antibodies against cd112r and uses thereof | |
| EA045980B1 (ru) | Антитела против рецептора полиовируса (pvr) и их применение | |
| WO2021051352A1 (zh) | 一种分离的抗原结合蛋白及其用途 |